On 2 October the FDA recorded a supplement to Accord Healthcare's abbreviated new drug application for generic clozapine (ANDA202873). Supplements to generic applications usually cover manufacturing, labelling alignment or packaging changes. The record does not describe the content of the change.
This is an administrative action, not a new safety finding, and it does not alter how clozapine is prescribed or monitored. It does not affect products marketed in India, where clozapine regulation sits with CDSCO.
- No change to clozapine prescribing or blood monitoring follows from this notice.
- Continue to follow the local neutrophil monitoring schedule for every patient on clozapine.
- Check that patients switched between generic clozapine brands keep the same dose and monitoring record.
Why it matters
Clozapine remains the drug of choice for treatment-resistant schizophrenia, so even routine supply changes are worth tracking.
Don't overread it
A supplement to a generic application is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free